Verfora acquires Spagyros Ltd. and expands its product portfolio
Press release, Thursday, 1 July 2021
Verfora, a subsidiary of Galenica, and Spagyros, a successful Swiss company in the manufacture and marketing of complementary medicines, have been maintaining a strategic partnership since 2018 that was also supported by Galenica with a small minority stake in Spagyros. With effect as of September 2021, Verfora will now acquire 100% of the share capital of Spagyros Ltd. This expansion step will not only enable Verfora in the future to meet the growing demand for phytotherapy and complementary medicines through its own products, but the company will also be able to strengthen pharmacies and drugstores with the addition of a range of products requiring intensive consultation. At the same time, this acquisition further strengthens Verfora’s leading position in the Swiss consumer healthcare (CHC) market.
Phytotherapy and complementary medicines:
a consultation-intensive field with growth potential
With the acquisition of Spagyros, Verfora is strengthening and opening up the interesting fields of phytotherapy, gemmotherapy, spagyrics and homoeopathy. These include well-known brands such as Spagyrom® (sore throat lozenges and cold drops), Spagymun® Abwehrkräfte (defences) or Spagyros Ribes nigrum® Gemmospray (mouth spray for colds and hay fever). Furthermore, Spagyros offers comprehensive education and training programmes in the fields of spagyrics, homoeopathy and gemmotherapy, which are recognised by the FPH (Swiss Association of Pharmacists), and the Swiss Druggists’ Association.
Other press releases
Ad hoc announcement pursuant to Art. 53 LR, Monday, 20 December 2021
Press release, Tuesday, 30 November 2021
Ad hoc announcement pursuant to Art. 53 LR, Tuesday, 3 August 2021